27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
H.C. Wainwright’s Swayampakula Ramakanth believes if the VTS gene therapy platform is successfully developed by Vascular Biogenics Ltd (NASDAQ: VBLT), it could revolutionize the multi-billion dollar angiogenesis inhibitor market.
Ramakanth initiated coverage of the company with a Buy rating and price target of $11.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Novel Therapy
The analyst mentioned that the company is developing a novel anti-angiogenesis therapy for solid tumors, and that compared to the currently available anti-angiogenesis drugs, Vascular Biogenics’ gene therapy offers several advantages, such as lower toxicity, tissue-specific activity and simpler dosing regimen.
“Currently, we expect VBL’s lead gene therapy product, VB-111, to reach the market in 2019 and achieve risk-adjusted annual sales of $386M by 2026,” Ramakanth stated.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
VB-111 has already demonstrated significant efficacy in the Phase 2 study in recurrent glioblastoma multiforme (rGBM), which is a highly aggressive yet difficult to treat brain tumor.
Vascular Biogenics initiated a pivotal Phase 3 trial for VB-111 in rGBM in 2H15 and the analyst believes that this could be the first drug to receive approval for rGBM since 2009.
“In addition to the GBM program, the company is also investigating the use of VB-111 for the treatment of ovarian and thyroid cancers in mid-stage studies,” according to the H.C. Wainwright report.
Multiple Catalysts
Ramakanth pointed out there were several upcoming catalysts for the company, including the expected top-line results from the GLOBE study in 1Q18.
The other catalysts that could drive share price appreciation include “1) full results from the Phase 2 study in thyroid cancer (4Q16); 2) initiation of the Phase 2b study in ovarian cancer (late-2016); and 3) interim analysis of the GLOBE study (1H17).”
In addition, Vascular Biogenics has several follow-on products in its pipeline.
At time of writing, Vascular Biogenics was up 8.23 percent on the day, trading at $4.28.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.